問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Rheumatology

Division of Dermatology

更新時間:2023-09-19

張雲亭Chang, Yun-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 8 years 1 個月

篩選

List

70Cases

2024-01-01 - 2028-04-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-10-10 - 2027-07-14

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2011-05-01 - 2014-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-02-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-10-29 - 2021-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-12-31 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Tildrakizumab

Participate Sites
9Sites

Recruiting9Sites

2021-09-01 - 2023-07-31

Phase II

Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis
  • Condition/Disease

    Prurigo Nodularis/Pruritis

  • Test Drug

    KPL-716/ vixarelimab

Participate Sites
4Sites

Recruiting4Sites

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)
  • Condition/Disease

    Mild Alzheimer′s Disease

  • Test Drug

    LY3314814

Participate Sites
10Sites

Terminated10Sites